Isolation and characterization of α-glucosidase inhibitor from the fungus Ganoderma lucidum

Journal of Microbiology

Volumn 42, Issue 3, 2004, Pages 223-227

  Kim, Shin Duk ^a   Hong, Joon Nho ^a  

^a Seokyeong University   (South Korea)

Author keywords

glucosidase inhibitor; Competitive inhibitor; Ganoderma lucidum; Reversible

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; SKG 3; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIALYSIS; ENZYME ACTIVITY; GANODERMA LUCIDUM; IC 50; NONHUMAN; PHYSICAL CHEMISTRY;

ALPHA-GLUCOSIDASES; BINDING, COMPETITIVE; DRUGS, CHINESE HERBAL; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; KINETICS; PLANT EXTRACTS; REISHI;

FUNGI; GANODERMA; GANODERMA LUCIDUM;

EID: 6344280078     PISSN: 12258873     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Asano, N. 2003. Glycosidase inhibitors: Update and perspectives on practical use. Glycobiology 13, 93R-104R.
2. Cenci di Bello, I., G. Fleet, K. Namgoong, K. Tadano, and B. Winchester. 1989. Structure-activity relationship of swainsonine: inhibition of human α-mannosidase by swainsonine analogues. Biochem. J. 259, 855-861.
3. Fischer, P., M. Collin, G. Karlsson, W. James, T. Butters, S. Davis, S. Gordon, R. Dwek, and F. Platt. 1995. The α-glucosidase inhibitor, N-butyldeoxynojirimycin inhibits human immunodeficiency virus entry at the level of post-CD4 binding. J. Virol. 69, 5791-5797.
4. Hikino, H., C. Konno, Y. Mirin, and T. Hayashi. 1985. Isolation and hypoglycemic activity of Ganoderans A and B, glycans of Ganoderma lucidum fruit bodies. Pla. Med. 51, 339-340.
5. Jacob, G.S. 1995. Glycosylation inhibitors in biology and medicine. Curr. Opin. Struct. Biol. 5, 605-611.
6. Kornfeld, R. and S. Kornfeld. 1985. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631-664.
7. Min, B.S., J.J. Gao, N. Nakamura, and M. Hattori. 2000. Triterpenes from the spores of Ganoderma lucidum and their cytotoxicity against meth-A and LLC tumor cells. Chem. Pharm. Bull. 48, 1026-1033.
8. 2 in weir vine and correlation with toxicity. J. Nat. Prod. 58, 878-886.
9. Molyneux, R., R. Nash, and N. Asano. 1996. The chemistry and biological activity of calystegines and related nortropane alkaloids, p. 303-343. In S. Pelletier (ed.), Alkaloids: Chemical and Biological Perspectives, 11. Elsevier Science Ltd, Oxford, UK.
10. Murai, A., K. Iwamura, M. Takada, K. Ogawa, T. Usui, and J. Okumura. 2002. Control of postprandial hyperglycaemia by galactosyl maltobionolactone and its novel anti-amylase effect in mice. Life Sci. 71, 1405-1415.
11. O'Dea, K. and J. Turton. 1985. Optimum effectiveness of intestinal α-glucosidase inhibitors. Am J Clin Nutr. 41, 511-516.
12. Pan, Y., J. Ghidoni, and D. Elbein. 1993. The effects of castanospermine and swainsonine on the activity and synthesis of intestinal sucrase. Arch. Biochem. Biophys. 303, 134-144.
13. Saul, R., J. Chambers, R. Molyneux, and A. Elbein. 1983. Castano-spemine, a tetrahydroxylated alkaloid that inhibits β-glucosidase and β-glucocerebrosidase. Arch. Biochem. Biophys. 221, 593-597.
14. Sunkara, P., T. Bowlin, P. Liu, and A. Sjoerdsma. 1987. Antiretroviral activity of castanospermine and deoxynojirimycin, specific inhibitors of glycoprotein processing. Biochem. Biophys. Res. Commun. 148, 206-210.
15. Watson, A., G. Fleet, N. Asano, R. Molyneux, and R. Nash. 2001. Polyhydroxylated alkaloids-natural occurrence and therapeutic applications. Phytochemistry 56, 265-295.